Rechte & Gesellschaft
New PRIME Tools to Accelerate Development of Medicines in the EU
The European Medicines Agency (EMA) has launched new features of PRIME, its scheme designed to enhance support for the development of medicines addressing unmet medical needs. These new features aim to accelerate the assessment and approval process for innovative therapies, ensuring that patients have faster access to potentially life-saving treatments. The enhancements are expected to streamline communication between the EMA and medicine developers.